Dipeptidyl peptidase (DPP)-4 is a ... that GIP and GLP-1 receptor-dependent pathways represent the dominant mechanisms transducing the glucoregulatory actions of DPP-4 inhibitors in vivo.

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i ... dipeptidyl peptidase-4 inhibitors (DPP-4i) in male patients with ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

Metabolic control can be improved markedly by administration of exogenous GLP-1, but the ... that inhibit DPP-4, thereby prolonging the duration of endogenous incretin action, have, therefore ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

The researchers reviewed 601 published trials of older people to investigate whether the efficacy of three medications — DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — was affected ...

"GLP-1 also tells the brain that there's fluid in the gastrointestinal tract, so you should start feeling full and stop ...

Treatment with any class of therapy was associated with an HbA1c reduction of 0.5 to 1.5 percentage points compared with placebo. SGLT2 inhibitors and GLP-1s, but not DPP-IV inhibitors ...

announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable alternatives to medications that may support metabolic ...